Literature DB >> 34315779

Prediction of Pregnancy-Induced Changes in Secretory and Total Renal Clearance of Drugs Transported by Organic Anion Transporters.

Jinfu Peng1, Mayur K Ladumor1, Jashvant D Unadkat2.   

Abstract

Pregnancy can significantly change the pharmacokinetics of drugs, including those renally secreted by organic anion transporters (OATs). Quantifying these changes in pregnant women is logistically and ethically challenging. Hence, predicting the in vivo plasma renal secretory clearance (CLsec) and renal CL (CLrenal) of OAT drugs in pregnancy is important to design correct dosing regimens of OAT drugs. Here, we first quantified the fold-change in renal OAT activity in pregnant versus nonpregnant individual using available selective OAT probe drug CLrenal data (training dataset; OAT1: tenofovir, OAT2: acyclovir, OAT3: oseltamivir carboxylate). The fold-change in OAT1 activity during the 2nd and 3rd trimester was 2.9 and 1.0 compared with nonpregnant individual, respectively. OAT2 activity increased 3.1-fold during the 3rd trimester. OAT3 activity increased 2.2, 1.7 and 1.3-fold during the 1st, 2nd, and 3rd trimester, respectively. Based on these data, we predicted the CLsec, CLrenal and total clearance ((CLtotal) of drugs in pregnancy, which are secreted by multiple OATs (verification dataset; amoxicillin, pravastatin, cefazolin and ketorolac, R-ketorolac, S-ketorolac). Then, the predicted clearances (CLs) were compared with the observed values. The predicted/observed CLsec, CLrenal, and CLtotal of drugs in pregnancy of all verification drugs were within 0.80-1.25 fold except for CLsec of amoxicillin in the 3rd trimester (0.76-fold) and cefazolin in the 2nd trimester (1.27-fold). Overall, we successfully predicted the CLsec, CLrenal, and CLtotal of drugs in pregnancy that are renally secreted by multiple OATs. This approach could be used in the future to adjust dosing regimens of renally secreted OAT drugs which are administered to pregnant women. SIGNIFICANCE STATEMENT: To the authors' knowledge, this is the first report to successfully predict renal secretory clearance and renal clearance of multiple OAT substrate drugs during pregnancy. The data presented here could be used in the future to adjust dosing regimens of renally secreted OAT drugs in pregnancy. In addition, the mechanistic approach used here could be extended to drugs transported by other renal transporters.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34315779      PMCID: PMC8626639          DOI: 10.1124/dmd.121.000557

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.579


  51 in total

1.  Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008.

Authors:  Allen A Mitchell; Suzanne M Gilboa; Martha M Werler; Katherine E Kelley; Carol Louik; Sonia Hernández-Díaz
Journal:  Am J Obstet Gynecol       Date:  2011-04-22       Impact factor: 8.661

2.  Pregnancy reduces the accuracy of the estimated glomerular filtration rate based on Cockroft-Gault and MDRD formulas.

Authors:  Patricia M J L Koetje; Julia J Spaan; Jeroen P Kooman; Marc E A Spaanderman; Louis L Peeters
Journal:  Reprod Sci       Date:  2010-11-15       Impact factor: 3.060

3.  Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.

Authors:  Venkateswaran C Pillai; Kelong Han; Richard H Beigi; Gary D Hankins; Shannon Clark; Mary F Hebert; Thomas R Easterling; Anne Zajicek; Zhaoxia Ren; Steve N Caritis; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2015-08-18       Impact factor: 4.335

Review 4.  Should pregnant women receive lower or higher medication doses?

Authors:  Andreas Austgulen Westin; Arne Reimers; Olav Spigset
Journal:  Tidsskr Nor Laegeforen       Date:  2018-10-30

5.  Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.

Authors:  Maïlys De Sousa Mendes; Deborah Hirt; Cécile Vinot; Elodie Valade; Gabrielle Lui; Claire Pressiat; Naïm Bouazza; Frantz Foissac; Stephane Blanche; Minh Patrick Lê; Gilles Peytavin; Jean-Marc Treluyer; Saik Urien; Sihem Benaboud
Journal:  Br J Clin Pharmacol       Date:  2016-01-12       Impact factor: 4.335

Review 6.  Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach.

Authors:  Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Down-regulation of brush border efflux transporter expression in the kidneys of pregnant mice.

Authors:  Lindsay L Yacovino; Christopher J Gibson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2012-08-15       Impact factor: 3.922

8.  A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation.

Authors:  Mayur K Ladumor; Aarzoo Thakur; Sheena Sharma; Aravind Rachapally; Sarang Mishra; Priyanka Bobe; V Kameswara Rao; Praneetha Pammi; Hari Kangne; David Levi; Ankit Balhara; Sriram Ghandikota; Anupama Joshi; Vivek Nautiyal; Bhagwat Prasad; Saranjit Singh
Journal:  Sci Rep       Date:  2019-07-04       Impact factor: 4.379

9.  Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study.

Authors:  M F Hebert; T R Easterling; B Kirby; D B Carr; M L Buchanan; T Rutherford; K E Thummel; D P Fishbein; J D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2008-02-20       Impact factor: 6.903

10.  The impact of chronic kidney disease Stages 3-5 on pregnancy outcomes.

Authors:  Kate Wiles; Philip Webster; Paul T Seed; Katy Bennett-Richards; Kate Bramham; Nigel Brunskill; Sue Carr; Matt Hall; Rehan Khan; Catherine Nelson-Piercy; Louise M Webster; Lucy C Chappell; Liz Lightstone
Journal:  Nephrol Dial Transplant       Date:  2021-11-09       Impact factor: 5.992

View more
  2 in total

Review 1.  Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.

Authors:  Ankit Balhara; Aditya R Kumar; Jashvant D Unadkat
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

2.  Application of a Physiologically Based Pharmacokinetic Model to Predict Cefazolin and Cefuroxime Disposition in Obese Pregnant Women Undergoing Caesarean Section.

Authors:  Hanadi H Alrammaal; Khaled Abduljalil; Victoria Hodgetts Morton; R Katie Morris; John F Marriott; Hsu P Chong; Hannah K Batchelor
Journal:  Pharmaceutics       Date:  2022-05-30       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.